Iterum Therapeutics (ITRM)
(Delayed Data from NSDQ)
$1.06 USD
-0.04 (-3.64%)
Updated Aug 8, 2024 03:59 PM ET
After-Market: $1.06 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth D Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
ITRM 1.06 -0.04(-3.64%)
Will ITRM be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for ITRM based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for ITRM
Iterum (ITRM) Plans Early Submission of UTI Drug NDA, Stock Up
Avalo (AVTX) Fails to Meet Goal in Asthma Study, Stock Down 89%
ITRM: What are Zacks experts saying now?
Zacks Private Portfolio Services
Catalyst (CPRX) to Gain DMD Drug Licensing Rights From Santhera
Beat the Market the Zacks Way: Uber, VirTra, Oracle in Focus
Baudax (BXRX) Up on New Neuromuscular Blocking Agent Study Data
Other News for ITRM
Iterum Therapeutics to Report Second Quarter 2024 Financial Results on August 14, 2024
Iterum Therapeutics Announces Expiration and Results of Rights Offering
Iterum Therapeutics Broadens Patent Estate for Oral Sulopenem
Iterum Therapeutics broadens patent estate for oral sulopenem
Iterum Therapeutics Commences Rights Offering